heterogeneous nuclear ribonucleoprotein K pseudogene 4Genealiases: []
Q-omics provides the consensus-scored HNRNPKP4 profile across patient tissues and cancer cell-line models. HNRNPKP4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HNRNPKP4 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, HNRNPKP4 RNA expression shows 18,456 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where HNRNPKP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPKP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPKP4 survival associations across molecular data types. HNRNPKP4 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPKP4 RNA expression–survival associations across cancer types. High HNRNPKP4 expression shows unfavorable associations in MESO, ACC, LIHC and LGG, but favorable associations in KIRC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HNRNPKP4 RNA expression.
This table summarizes HNRNPKP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPKP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPKP4 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, HNSC, BRCA and LIHC. The COAD box plot shows higher HNRNPKP4 RNA expression in tumor versus normal tissue (log2 FC = +1.412, t-test p < 0.001).
This table shows molecular features associated with HNRNPKP4 in patient tissues and cancer cell lines. In patient samples, HNRNPKP4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
